Neurocutaneous syndromes: Neurofibromatosis 1, neurofibromatosis 2, and tuberous sclerosis

Current Opinion in Neurology

Volumn 10, Issue 2, 1997, Pages 131-136

  Korf, Bruce R ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; HUMAN; LEARNING DISORDER; MOLECULAR GENETICS; NEUROFIBROMATOSIS; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR GENE;

CHILD; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, DOMINANT; GENES, TUMOR SUPPRESSOR; HUMANS; MOLECULAR BIOLOGY; NEUROFIBROMATOSIS 1; NEUROFIBROMATOSIS 2; TUBEROUS SCLEROSIS;

EID: 0030946514     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Gutmann DH, Collins FS: The neurofibromatosis type 1 gene and its protein product, neurofibromln. Neuron 1993, 10:335-343.
2. Viskochil D, White R, Cawthon R: The neurofibromatosis type 1 gene. Annu Rev Neurosci 1993, 16:183-205.
3. Chapman CA, Waber DP, Bassett N, Urion DK, Korf BR: Neurobehavioral profiles of children with neurofibromatosis 1 referred for learning disabilities are sex-specific. Amer J Med Genet 1996, 67:127-132.
4. North K, Joy P, Yuille D, Cocks N, Mobbs E, Hutchins P, McHugh K, de Silva M: Specific learning disability in children with neurofibromatosis type 1: significance of MRI abnormalities. Neurology 1994, 44:878-883.
5. Hofman KJ, Harris EL, Bryan RN, Denckla MB: Neurofibromatosis type 1: the cognitive phenotype. J Pediatr 1994, 124:S1-S8.
6. Ferner RE, Chaudhuri R, Bingham J, Cox T, Hughes RAC: MRI in neurofibromatosis 1. The nature and evolution of increased intensity T2 weighted lesions and their relationship to intellectual impairment. J Neurol Neurosurg Psychiatry 1993, 56:492-495.
7. Bognanno JR, Edwards MK, Lee TA, Dunn DW, Roos KL, Klatte EC: Cranial MR imaging in neurofibromatosis. Am J Radiol 1988, 151:381-388.
8. Duffner PK, Cohen ME, Seidel FG, Shucard DW: The significance of MRI abnormalities in children with neurofibromatosis. Neurology 1989, 39:373-378.
9. 2-weighted signal intensity, but not with their volume or location.
10. •].
11. Listernick R, Charrow J, Greenwald M, Mets M: Natural history of optic pathway tumors in children with neurofibromatosis type 1 : a longitudinal study. J Pediatr 1994, 125:63-66
12. Tonsgard JH, Short MP, Kwak S, Dachman A: Computed tomographic imaging in neurofibromatosis. Ann Neurol 1996, 40:278
13. Van Es S, North KN, McHugh K, de Silva M MRI findings in children with neurofibromatosis type 1: a prospective study. Pediatr Radiol 1996, 26:478-487.
14. Molloy PT, Bilaniuk LT, Vaughan SN, Needle MN, Liu GT, Zackai EH: • Brainstem tumors in patients with neurofibromatosis type 1: a distinct clinical entity. Neurol 1995, 45:1897-1902. Brainstem tumors in children with NF1 may have a different natural history than brainstem tumors in individuals who do not have NF1.
15. •] this study examined the natural history of brainstem tumors in children with NF1, also showing a difference in behavior from brainstem tumors in the general population.
16. Shen MH, Harper PS, Upadhyaya M: Molecular genetics of neurofibromatosis type 1 (NF1). J Med Genet 1996, 33:2-17.
17. Heim RA, Kam-Morgan LNW, Binnie CG, Corns DD, Cayouette MC, •• Farber RA, Aylsworth AS, Silverman LM, Luce MC: Distribution of 13 truncating mutations in the neurofibromatosis 1 gene. Hum Mol Genet 1995, 4:975-981. The protein truncation assay is, to date, the most sensitive general screen for NF1 mutations. The assay identifies the site of mutation (if the mutation leads to premature termination of translation), but the mutation itself still must be identified by gene sequencing.
18. Kayes LM, Burke W, Riccardi VM, Bennett R, Ehrlich P, Rubenstein AS: Deletions spanning the neurofibromatosis 1 gene: identification and phenotype of five patients. Am J Hum Genet 1994, 54:424-436.
19. Wu BL, Austin MA, Schneider GH, Boles RG, Korf BR: Deletion of the • entire NF1 gene detected by FISH: four deletion patients associated with severe manifestations. Am J Med Genet 1995, 59:528-535. Fluorescence in-situ hybridization provides a simple way to identify large NF1 gene deletions that are associated with early onset of neurofibromas and developmental delay.
20. Leppig KA, Viskochil D, Neil S, Rubenstein A, Johnson VP, Zhu XL, Brothman AR, Stephens K: The detection of contiguous gene deletions at the neurofibromatosis 1 locus with fluorescence in situ hybridization. Cytogenet Cell Genet 1996, 72:95-98.
21. Upadhyaya M, Roberts SH, Maynard J, Sorour E, Thompson PW, Vaughan M, Wilkie AOM, Hughes HE: A cytogenetic deletion, del(17)(q11.22q21.1). in a patient with sporadic neurofibromatosis type 1 (NF1) associated with dysmorphism and developmental delay. J Med Genet 1996, 33:148-152.
22. Colman SD, Rasmussen SA, Ho VT, Abernathy CR, Wallace MR: Somatic •• mosalcism in a patient with neurofibromatosis type 1. Am J Hum Genet 1996, 58:484-490. This is the first report of somatic mosaicism for an NF1 gene mutation. The patient did not have segmental NF. It is likely that mosaicism will be found in many sporadically affected individuals with NF1.
23. Andrews JD, Mancini DN, Singh SM, Rodenhiser DI: Site and sequence specific DNA methylation in the neurofibromatosis (NF1) gene includes C5893T: the site of the recurrent substitution mutation in exon 31. Hum Molec Genet 1996, 5:503-507.
24. Li Y, O'Connell P, Breidenbach HH, Cawthon R, Stevens J, Xu G, Neil S, Robertson M, White R, Viskochil D: Genomlc organization of the neurofibromatosis 1 gene (NF1). Genomics 1995, 25:9-18.
25. Purandare SM, Breidenbach HH, Li Y, Zhu XL, Sawada S, Neil SM, Brothman A, White R, Cawthon R, Viskochil D: Identification of neurofibromatosis 1 (NF1) homologous loci by direct sequencing, fluorescence in situ hybridization, and PCR amplification of somatic cell hybrids. Genomics 1995, 30:476-485.
26. Purandare SM, Cawthon R, Nelson LM, Sawada S, Watkins WS, Ward K, Jorde LB, Viskochil DH: Genotyplng of PCR-based polymorphisms and linkage disequilibrium analysis at the NF1 locus. Am J Hum Genet 1996, 59:159-166.
27. Morcos P, Thapar N, Tusneem N, Stacey D, Tamanoi F: Identification of neurofibromin mutants that exhibit allele specificity or increased ras affinity resulting in suppression of activated ras alleles. Mol Cell Biol 1996, 16:2496-2503.
28. Colman SD, Williams CA, Wallace MR: Benign neurofibromas in type • 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene. Nature Genet 1995, 11:90-92. Benign neurofibromas have loss of heterozygosity of the NF1 gene, as predicted for a tumor suppressor model of pathogenesis.
29. Guha A, Lau N, Huvar I, Gutmann D, Provias J, Pawson T, Boss G: Ras-GTP levels are elevated in human NF1 peripheral nerve tumors. Oncogene 1996, 12:507-513.
30. Sawada S, Florell S, Purandare SM, Ota M, Stephens K, Viskochil D: •• Identification of NF1 mutations in both alleles of a dermal neurofibroma. Nature Genet 1996, 14:110-112. This is the first direct demonstration of homozygous deletion of NF1 in a benign neurofibroma, providing confirmation of the tumor suppressor hypothesis.
31. Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P, Lange BJ, Freedman MH, McCormick F, Jacks T, Shannon K: Loss of NF1 results In activation of the Ras signalling pathway and leads to aberrant growth in haematopoietic cells. Nature Genet 1996, 12:144-148.
32. Largaespada DA, Brannan CI, Jenkins NA, Copeland NG: Nf1 deficiency causes Ras-mediated granulocyte macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nature Genet 1996, 12:137-143.
33. Hall CC, Watkins JD, Ferguson SB, Foley LH, Georgopapadakou NH: Inhibitors of farnesyltransferase and RAS processing peptidase. Biochem Biophys Res Commun 1995, 217:728-732.
34. Yan N, Ricca C, Fletcher J, Glover T, Seizinger BR, Manne V: Farnesyl•• transferase inhibitors block the neurofibromatosis type 1 (NF1) malignant phenotype. Cancer Res 1995, 55:3569-3575. Farnesyltransferase inhibitors prevent binding of Ras to the inner cell membrane, its site of action. These drugs are a major candidate for future therapeutic trials in NF1.
35. den Bakker MA, Tascilar M, Riegman PHJ, Hekman ACP, Boersma W, Janssen PJA, de Jong TAW, Hendriks W, van der Kwast TH, Zwarthoff EC: Neurofibromatosis 2 protein co-localizes with elements of the cytoskeleton. Am J Pathol 1995, 147:1339-1349.
36. Gonzalez-Agosti C, Xu L, Pinney D, Beauchamp R, Hobbs W, Gusella J, Ramesh V: The merlin tumor suppressor localizes preferentially in membrane ruffles. Oncogene 1996, 13:1239-1247.
37. Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, Eldridge R, Kley N, Menon AG, Pulaski K et al:. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993, 72:791-800.
38. Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, Hoang-Xuan K, Demczuk S, Oesmaze C, Plougastel B et al.: Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993, 363:515-521.
39. Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N: Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 1994, 52:450-461.
40. Parry DM, MacCollin MM, Kaiser-Kupfer MI, Pulaski K, Nicholson HS, • Bolesta M, Eldridge R, Gusella JF: Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet 1996, 59:529-539. Mutations that cause premature termination of translation of the NF2 gene product tend to be associated with more severe phenotype than single codon changes, for the most part.
41. Ruttledge MH, Andermann AA, Phelan CM, Claudio JO, Han FY, Chretien N, • Rangaratnam S, MacCollin M, Short P, Parry D et al.: Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet 1996, 59:331-342. Another study establishing genotype-phenotype correlations in NF2.
42. Scoles DR, Baser ME, Pulst S-M: A missense mutation in the neurofibromatosis 2 gene occurs in patients with mild and severe phenotypes. Neurology 1996, 47:544-546.
43. MacCollin M, Braverman N, Viskochil D, Ruttledge M, Davis K, Ojemann R, Gusella J, Parry DM: A point mutation associated with a severe phenotype of neurofibromatosis 2. Ann Neurol 1996, 40:440-445.
44. Kluwe L, Mautner VF: A missense mutation in the NF2 gene results in moderate and mild clinical phenotypes of neurofibromatosis type 2. Hum Genet 1996, 97:224-227.
45. Baser ME, Ragge NK, Riccardi VM, Janus T, Gantz B, Pulst SM: Phenotypic variability in monozygotic twins with neurofibromatosis 2. Am J Med Genet 1996, 64:563-567.
46. Seizinger BR, Rouleau G, Ozelius LJ, Lane AH, St George-Hyslop P, Huson S, Gusella JF, Martuza RL: Common pathogenetic mechanism for three tumor types in bilateral acoustic neurofibromatosis. Science 1987, 236:317-319.
47. De Vitis LR, Tedde A, Vitelli F, Ammannati F, Mennonna P, Bono P, Grammatico B, Grammatico P, Radice P, Bigozzi U et al: Analysis of the neurofibromatosis type 2 gene in different human tumors of neuroectodermal origin. Hum Genet 1996, 97:638-641.
48. De Vitis LR, Tedde A, Vitelli F, Ammannati F, Mennonna P, Bigozzi U, Montali E, Papi L: Screening for mutations in the neurofibromatosis 2 (NF2) gene in sporadic meningiomas. Hum Genet 1996, 97:632-637.
49. Ng HK, Lau KM, Tse JYM, Lo KW, Wong JHC, Poon WS, Huang DP: Combined molecular genetic studies of chromosome 22q and the neurofibromatosis type 2 gene in central nervous system tumors. Neurosurgery 1995, 37:764-773.
50. Antinheimo J, Haapasalo H, Seppälä M, Sainio M, Carpen O, Jääskeläinen J: Prollferative potential of sporadic and neurofibromatosis 2-associated schwannomas as studied by MIB-1 (Ki-67) and PCNA labeling. J Neuropathol Exp Neurol 1995, 54:776-782.
51. Povey S, Burley MW, Attwood J, Benham F, Hunt D, Jeremiah SJ, Franklin D, Gillett G, Malas S, Robson EB: Two loci for tuberous sclerosis: one on 9q34 and one on 16p13. Ann Hum Genet 1994, 58:107-127.
52. European Chromosome 16 Tuberous Sclerosis Consortium: Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993, 75:1305-1315.
53. Webb DW, Fryer AE, Osborne JP: Morbidity associated with tuberous • sclerosis: a population study. Dev Med Child Neurol 1996, 38:146-155. This population-based study is a useful source of information on the natural history of tuberous sclerosis and its complications.
54. Webb DW, Clarke A, Fryer A, Osborne JP: The cutaneous features of tuberous sclerosis: a population study. Br J Dermatol 1996, 135:1-5.
55. Cook JA, Oliver K, Mueller RF, Sampson J: A cross sectional study of renal involvement in tuberous sclerosis. J Med Genet 1996, 33:480-484.
56. O'Hagan AR, Ellsworth R, Secic M, Rothner AD, Brouhard BH: Renal manifestations of tuberous sclerosis complex. Clin Pediatr (Phila) 1996, 35:483-489.
57. Bosi G, Lintermans JP, Pellegrino PA, Svaluto-Moreolo G, Vliers A: The natural history of cardiac rhabdomyoma with and without tuberous sclerosis. Acta Paediatrica 1996, 85:928-931.
58. Murrell J, Trofatter J, Rutter M, Cutone S, Stotler C, Rutter J, Long K, Turner A, Deaven L, Buckler A, McCormick MK: A 500-kilobase region containing the tuberous sclerosis locus (TSC1) in a 1.7-megabase YAC and cosmid contig. Genomics 1995, 25:59-65.
59. Au KS, Murrell J, Buckler A, Blanton SH, Northrup H: Report of a critical recombination further narrowing the TSC1 region. J Med Genet 1996, 33:559-561.
60. Mor O, Duhig T, Fried M: A high frequency polymorphism in the candidate region for tuberous sclerosis 1 (TSC1) at 9q34. Ann Hum Genet 1996, 60:259-260.
61. Henske EP, Scheithauer BW, Short MP, Wollmann R, Nahmias J, Hornigold N, Van Slegtenhorst M, Welsh CT, Kwiatkowski DJ: Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. Am J Hum Genet 1996, 59:400-406.
62. Sepp T, Yates JRW, Green AJ: Loss of heterozygoslty in tuberous sclerosis hamartomas. J Med Genet 1996, 33:962-964.
63. Green AJ, Sepp T, Yates JRW: Clonality of tuberous sclerosis harmatomas shown by non-random X-chromosome inactivation. Hum Genet 1996, 97:240-243.